Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

被引：8

作者：

Tuchayi, Abuzar Moradi ^{[1
]}

Yadav, Surekha ^{[1
]}

Jiang, Fei ^{[2
]}

Kim, Sarasa T. ^{[1
]}

Saelee, Rachelle K. ^{[1
]}

Morley, Amanda ^{[1
]}

Juarez, Roxanna ^{[1
]}

Lawhn-Heath, Courtney ^{[1
]}

Wang, Yingbing ^{[1
]}

de Kouchkovsky, Ivan ^{[3
]}

Hope, Thomas A. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94117 USA

[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA

[3] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA

来源：

JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷 / 05期

关键词：

genitourinary; oncology; radionuclide therapy; 177; Lu-; PSMA-617; toxicities; RESISTANT PROSTATE-CANCER; CRITERIA; OUTCOMES; MEN;

D O I：

10.2967/jnumed.123.266842

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

We report our initial real -world experience with 177 Lu-PSMA-617 radioligand therapy. Methods: We performed a retrospective review of patients treated with 177 Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate -specific antigen by 50% (PSA50), and toxicities were evaluated. Results: Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of 18 (39%) patients who did not meet the TheraP PSMA imaging criteria achieved a PSA50. Nineteen of 31 (61%) patients who did not meet the VISION laboratory criteria achieved a PSA50. Sixty-three patients had a delay or stoppage in therapy, which was due to a good response in 19 patients and progressive disease in 14 patients. Of 10 patients with a good response who restarted treatment, 9 subsequently achieved a PSA50 on retreatment. The most common toxicities were anemia (33%) and thrombocytopenia (21%). Conclusion: At our center, patients who did not meet the TheraP PSMA imaging criteria or the VISION laboratory criteria benefited from 177 Lu-PSMA-617 radioligand therapy.

引用

页码：735 / 739

页数：5

共 14 条

[1] Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT) [J].

Emmett, Louise ;

John, Nikeith ;

Pathmanandavel, Sarennya ;

Counter, William ;

Ayers, Maria ;

Sharma, Shikha ;

Agrawal, Shikha ;

Poole, Aron ;

Hovey, Elizabeth ;

Pranavan, Ganes ;

Gedye, Craig ;

Mallesara, Girish ;

Guminski, Alex ;

Lee, Adrian ;

Stockler, Martin R. ;

Hickey, Adam ;

Eu, Peter ;

Joshua, Anthony M. ;

Crumbaker, Megan ;

Nguyen, Andrew .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15

[2] Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study [J].

Gafita, Andrei ;

Calais, Jeremie ;

Grogan, Tristan R. ;

Hadaschik, Boris ;

Wang, Hui ;

Weber, Manuel ;

Sandhu, Shahneen ;

Kratochwil, Clemens ;

Esfandiari, Rouzbeh ;

Tauber, Robert ;

Zeldin, Anna ;

Rathke, Hendrik ;

Armstrong, Wesley R. ;

Robertson, Andrew ;

Thin, Pan ;

D'Alessandria, Calogero ;

Rettig, Matthew B. ;

Delpassand, Ebrahim S. ;

Haberkorn, Uwe ;

Elashoff, David ;

Herrmann, Ken ;

Czernin, Johannes ;

Hofman, Michael S. ;

Fendler, Wolfgang P. ;

Eiber, Matthias .

LANCET ONCOLOGY, 2021, 22 (08) :1115-1125

[3] [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial [J].

Hofman, Michael S. ;

Emmett, Louise ;

Sandhu, Shahneen ;

Iravani, Amir ;

Joshua, Anthony M. ;

Goh, Jeffrey C. ;

Pattison, David A. ;

Tan, Thean Hsiang ;

Kirkwood, Ian D. ;

Ng, Siobhan ;

Francis, Roslyn J. ;

Gedye, Craig ;

Rutherford, Natalie K. ;

Weickhardt, Andrew ;

Scott, Andrew M. ;

Lee, Sze-Ting ;

Kwan, Edmond M. ;

Azad, Arun A. ;

Ramdave, Shakher ;

Redfern, Andrew D. ;

Macdonald, William ;

Guminski, Alex ;

Hsiao, Edward ;

Chua, Wei ;

Lin, Peter ;

Zhang, Alison Y. ;

McJannett, Margaret M. ;

Stockler, Martin R. ;

Violet, John A. ;

Williams, Scott G. ;

Martin, Andrew J. ;

Davis, Ian D. .

LANCET, 2021, 397 (10276) :797-804

[4]

Hope TA, 2022, J NUCL MED, V63, p14N

[5] The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy [J].

Karimzadeh, Amir ;

Heck, Matthias ;

Tauber, Robert ;

Solaris, Esteban ;

Nekolla, Stephan ;

Knorr, Karina ;

Haller, Bernhard ;

D'Alessandria, Calogero ;

Weber, Wolfgang A. ;

Eiber, Matthias ;

Rauscher, Isabel .

JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (08) :1252-1258

[6] Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial [J].

Kuo, Phillip H. ;

Benson, Taylor ;

Messmann, Richard ;

Groaning, Michael .

JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) :816-818

[7] Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology [J].

Nuhn, Philipp ;

De Bono, Johann S. ;

Fizazi, Karim ;

Freedland, Stephen J. ;

Grilli, Maurizio ;

Kantoff, Philip W. ;

Sonpavde, Guru ;

Sternberg, Cora N. ;

Yegnasubramanian, Srinivasan ;

Antonarakis, Emmanuel S. .

EUROPEAN UROLOGY, 2019, 75 (01) :88-99

[8] Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer [J].

Sartor, Oliver ;

de Bono, Johann ;

Chi, Kim N. ;

Fizazi, Karim ;

Herrmann, Ken ;

Rahbar, Kambiz ;

Tagawa, Scott T. ;

Nordquist, Luke T. ;

Vaishampayan, Nitin ;

El-Haddad, Ghassan ;

Park, Chandler H. ;

Beer, Tomasz M. ;

Armour, Alison ;

Perez-Contreras, Wendy J. ;

DeSilvio, Michelle ;

Kpamegan, Euloge ;

Gericke, Germo ;

Messmann, Richard A. ;

Morris, Michael J. ;

Krause, Bernd J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) :1091-1103

[9] Metastatic Prostate Cancer [J].

Sartor, Oliver ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (07) :645-657

[10] Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177 Lu-PSMA-617 Radioligand Therapy [J].

Seifert, Robert ;

Seitzer, Konstantin ;

Herrmann, Ken ;

Kessel, Katharina ;

Schaefers, Michael ;

Kleesiek, Jens ;

Weckesser, Matthias ;

Boegemann, Martin ;

Rahbar, Kambiz .

THERANOSTICS, 2020, 10 (17) :7812-7820

← 1 2 →